- Home
- SKK vs BRTX Comparison
SKK vs BRTX Comparison
Compare SKK & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKK
- BRTX
- Stock Information
- Founded
- SKK 2013
- BRTX 1997
- Country
- SKK Singapore
- BRTX United States
- Employees
- SKK N/A
- BRTX 11
- Industry
- SKK
- BRTX Managed Health Care
- Sector
- SKK
- BRTX Health Care
- Exchange
- SKK NYSE
- BRTX Nasdaq
- Market Cap
- SKK 12.3M
- BRTX 13.7M
- IPO Year
- SKK 2024
- BRTX N/A
- Fundamental
- Price
- SKK $0.74
- BRTX $1.67
- Analyst Decision
- SKK
- BRTX Strong Buy
- Analyst Count
- SKK 0
- BRTX 1
- Target Price
- SKK N/A
- BRTX $18.00
- AVG Volume (30 Days)
- SKK 76.7K
- BRTX 27.4K
- Earning Date
- SKK 02-14-2025
- BRTX 05-14-2025
- Dividend Yield
- SKK N/A
- BRTX N/A
- EPS Growth
- SKK N/A
- BRTX N/A
- EPS
- SKK N/A
- BRTX N/A
- Revenue
- SKK $8,631,000.00
- BRTX $401,000.00
- Revenue This Year
- SKK N/A
- BRTX $446.88
- Revenue Next Year
- SKK N/A
- BRTX $39.53
- P/E Ratio
- SKK N/A
- BRTX N/A
- Revenue Growth
- SKK N/A
- BRTX 175.03
- 52 Week Low
- SKK $0.61
- BRTX $1.03
- 52 Week High
- SKK $11.45
- BRTX $2.55
- Technical
- Relative Strength Index (RSI)
- SKK N/A
- BRTX 41.86
- Support Level
- SKK N/A
- BRTX $1.66
- Resistance Level
- SKK N/A
- BRTX $1.88
- Average True Range (ATR)
- SKK 0.00
- BRTX 0.08
- MACD
- SKK 0.00
- BRTX -0.01
- Stochastic Oscillator
- SKK 0.00
- BRTX 8.33
About SKK SKK HOLDINGS LIMITED
SKK Holdings Ltd is a civil engineering service provider that specializes in subsurface utility works in Singapore. It construct and maintain various public works and infrastructure projects that serve the society and the environment. Its projects are primarily the subsurface work related to projects undertaken by the Public Utilities Board (PUB) and Singapore Telecommunications Limited. The nature of these projects is related to repairing of pumping mains, sewer maintenance and pipe cable laying.
About BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.